Respirogen Revenue and Competitors
Estimated Revenue & Valuation
- Respirogen's estimated annual revenue is currently $310k per year.
- Respirogen's estimated revenue per employee is $155,000
Employee Data
- Respirogen has 2 Employees.
- Respirogen grew their employee count by 0% last year.
Respirogen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director Operations | Reveal Email/Phone |
Respirogen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is Respirogen?
Respirogen's technology will provide oxygen independent from damaged lungs. Acute respiratory distress syndrome (ARDS) is an acute severe lung disease commonly encountered in intensive care units (ICU). It can be caused by several triggers, including pneumonia or trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe hypoxaemia, which is refractory to oxygen treatment and requires assisted ventilation.
keywords:N/A
N/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 2 | 0% | N/A |
#2 | $0M | 2 | 0% | $12.1M |
#3 | $0.3M | 2 | 0% | N/A |
#4 | $0.2M | 2 | -89% | N/A |
#5 | $3M | 2 | 0% | N/A |